omniture
logo
Search
中山康方生物医药有限公司
Media Room

Latest News

rss

PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer

HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD...

2021-11-02 11:53 2073

Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors

HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Akeso, one of leading Chinese pharmaceutical innovation co...

2021-10-22 09:50 1607

Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma

HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Co...

2021-10-15 12:44 2066

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 24, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Nat...

2021-09-24 14:09 2038

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Nat...

2021-09-24 09:18 3712

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced t...

2021-08-06 09:39 28765

CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

HONG KONG, July 12, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal a...

2021-07-13 09:06 2242

Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor

HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK...

2021-06-30 16:00 13617

Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States

HONG KONG, May 24, 2021 /PRNewswire/ -- On May 24, 2021, Akeso, Inc. (HKEx: 9926.HK) announced that...

2021-05-24 18:17 3337
1 ... 34567